Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Phase 2

Terminated

Conditions: Lymphoma
Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorders
Multiple Myleoma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Peripheral blood stem cell (PBSC) transplantation
Drug: Etoposide
Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Drug: Doxorubicin
Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Drug: Vincristine
Drug: Filgrastim
Drug: Prednisone
Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)

First Posted Date: 2003-12-15

Last Posted Date: 2018-12-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 442

Registration Number: NCT00074490

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Phase 1

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2003-12-11

Last Posted Date: 2014-03-05

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00074139

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-12-11

Last Posted Date: 2023-07-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT00003927

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Waldenström Macroglobulinemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Lymphoblastic Lymphoma

Interventions: Drug: cyclophosphamide
Drug: etoposide
Radiation: iodine I 131 tositumomab
Procedure: quality-of-life assessment
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-12-11

Last Posted Date: 2017-08-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00073918

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Phase 2

Terminated

Conditions: Drug/Agent Toxicity by Tissue/Organ
Brain and Central Nervous System Tumors
Lymphoma
Thrombocytopenia

Interventions: Drug: Rituxan
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Etoposide phosphate
Drug: Carboplatin
Drug: Sodium thiosulfate
Drug: Neupogen
Drug: Neulasta
Drug: Cytarabine

First Posted Date: 2003-12-11

Last Posted Date: 2023-07-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00074165

Locations: 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: rituximab
Drug: Alemtuzumab
Drug: cyclophosphamide
Drug: pentostatin

First Posted Date: 2003-12-11

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 102

Registration Number: NCT00074282

Locations: 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 140 locations

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-12-11

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00074178

Locations: 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Not Applicable

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-12-11

Last Posted Date: 2015-01-29

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT00073879

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Combination Chemotherapy in Treating Women With Breast Cancer

Phase 3

Conditions: Breast Cancer

First Posted Date: 2003-12-05

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 350

Registration Number: NCT00003679

Locations: 🇬🇧
C.R.C. Beatson Laboratories, Glasgow, Scotland, United Kingdom

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-12-02

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 38

Registration Number: NCT00003388

Locations: 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸
Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸
Raritan Bay Medical Center, Perth Amboy, New Jersey, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy